Skip to main content

Table 4 Changes in ITSQ and PAM-D21 questionnaire scores

From: Insulin lispro low mixture twice daily vs basal insulin glargine once daily and prandial insulin lispro once daily as insulin intensification strategies in patients with type 2 diabetes: Latin American subpopulation analysis of a randomized trial

Variable, change from baseline

LM25 (N = 80)

IGL (N = 82)

Baseline

Change from baseline

Baseline

Change from baseline

ITSQ, mean (SD)

 Inconvenience of regimen

92.7 (10.7)

−1.5 (11.0)

92.2 (12.1)

0.5 (11.2)

 Lifestyle flexibility

82.9 (21.2)

−0.1 (24.1)

84.7 (17.6)

−4.8 (24.9)

 Glycemic control

80.9 (19.9)

6.9 (20.0)

78.3 (21.7)

10.3 (22.1)

 Hypoglycemic control

85.5 (14.7)

−2.7 (17.7)

85.7 (17.8)

0.1 (17.0)

 Insulin delivery device satisfaction

86.9 (15.7)

4.2 (16.1)

88.6 (14.3)

1.1 (10.6)

 Total score

86.5 (11.4)

1.1 (11.6)

86.8 (12.4)

1.2 (10.6)

PAM-D21, mean (SD)

 Convenience/flexibility

90.0 (16.0)

−0.7 (21.2)

91.7 (13.8)

−1.2 (16.8)

 Perceived effectiveness

74.6 (20.7)

5.9 (23.7)

72.0 (20.5)

12.0 (25.4)

 Emotional effects

84.2 (20.2)

1.0 (21.7)

86.8 (17.5)

−0.2 (22.4)

 Physical effects

87.0 (13.4)

1.0 (12.8)

90.5 (12.9)

1.1 (10.4)

  1. IGL once-daily basal insulin glargine plus once-daily prandial insulin lispro, ITSQ insulin treatment satisfaction questionnaire, LM25 75 % insulin lispro protamine suspension and 25 % insulin lispro solution, PAM-D21 perceptions about medications-diabetes 21, SD standard deviation